Key Points
- Immunome director Jean Jacques Bienaime bought 5,000 shares on May 15 at $20.70 each, a $103,500 purchase that increased his stake by 13.02% to 43,415 shares.
- Bienaime had also purchased 1,000 shares in March at an average price of $21.55, showing continued insider buying activity.
- Immunome recently beat quarterly EPS estimates with a loss of $0.48 per share versus the expected $0.60, while analysts currently hold a Moderate Buy consensus with an average target price of $32.82.
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) Director Jean Jacques Bienaime purchased 5,000 shares of the company's stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $20.70 per share, for a total transaction of $103,500.00. Following the completion of the purchase, the director owned 43,415 shares of the company's stock, valued at approximately $898,690.50. This trade represents a 13.02% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Jean Jacques Bienaime also recently made the following trade(s):
- On Wednesday, March 11th, Jean Jacques Bienaime purchased 1,000 shares of Immunome stock. The stock was acquired at an average cost of $21.55 per share, for a total transaction of $21,550.00.
Immunome Stock Performance
Shares of IMNM opened at $19.66 on Wednesday. Immunome, Inc. has a 52-week low of $7.83 and a 52-week high of $27.65. The business's 50 day moving average price is $21.91 and its two-hundred day moving average price is $21.27. The firm has a market cap of $2.23 billion, a PE ratio of -8.26 and a beta of 2.11.
Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.12. Research analysts predict that Immunome, Inc. will post -2.26 EPS for the current fiscal year.
Institutional Investors Weigh In On Immunome
Several institutional investors have recently bought and sold shares of the stock. Stoneridge Investment Partners LLC grew its holdings in Immunome by 5.4% during the third quarter. Stoneridge Investment Partners LLC now owns 12,174 shares of the company's stock worth $143,000 after buying an additional 620 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its holdings in Immunome by 6.1% during the third quarter. ANTIPODES PARTNERS Ltd now owns 10,892 shares of the company's stock worth $128,000 after buying an additional 631 shares in the last quarter. Creative Planning grew its holdings in Immunome by 4.0% during the third quarter. Creative Planning now owns 18,664 shares of the company's stock worth $219,000 after buying an additional 710 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in Immunome by 14.4% during the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company's stock worth $159,000 after buying an additional 935 shares in the last quarter. Finally, California State Teachers Retirement System grew its holdings in Immunome by 1.8% during the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company's stock worth $1,439,000 after buying an additional 1,167 shares in the last quarter. Institutional investors own 44.58% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms have recently commented on IMNM. Truist Financial upgraded Immunome to a "strong-buy" rating in a report on Monday, May 4th. Weiss Ratings restated a "sell (d-)" rating on shares of Immunome in a report on Tuesday, April 21st. Leerink Partners decreased their price objective on Immunome from $37.00 to $33.00 and set an "outperform" rating for the company in a report on Friday. Stephens decreased their price objective on Immunome from $33.00 to $30.00 and set an "overweight" rating for the company in a report on Wednesday, March 4th. Finally, Craig Hallum boosted their price objective on Immunome from $33.00 to $36.00 and gave the company a "buy" rating in a report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $32.82.
View Our Latest Stock Report on Immunome
About Immunome
(
Get Free Report)
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
